Redmile Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Redmile Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.2M	Buy	265,169 +91,310	+53%	+$5M	1.02%	22
2026 Q1	$9.82M	Buy	+173,859	New	+$10.1M	0.65%	23
2023 Q3	–	Sell	-489,208	Closed	-$42.4M	–	69
2023 Q2	$42.4M	Buy	489,208 +154,038	+46%	+$14.5M	1.63%	18
2023 Q1	$32.6M	Buy	+335,170	New	+$34.7M	1.41%	24
2022 Q3	–	Sell	-300,000	Closed	-$24.9M	–	71
2022 Q2	$24.9M	Buy	+300,000	New	+$23.9M	0.95%	30
2019 Q3	–	Sell	-97,191	Closed	-$8.32M	–	77
2019 Q2	$8.32M	Buy	+97,191	New	+$8.31M	0.24%	61
2018 Q1	–	Sell	-2,500	Closed	-$223K	–	67
2017 Q4	$223K	Buy	+2,500	New	+$217K	0.01%	67
2016 Q3	–	Sell	-322,394	Closed	-$25.1M	–	53
2016 Q2	$25.1M	Sell	322,394 -155,893	-33%	-$13.3M	2.4%	16
2016 Q1	$39.4M	Buy	+478,287	New	+$38.9M	4.04%	8
2015 Q4	–	Sell	-368,775	Closed	-$38.8M	–	58
2015 Q3	$38.8M	Buy	368,775 +161,031	+78%	+$21.5M	2.94%	15
2015 Q2	$28.4M	Buy	+207,744	New	+$25.7M	2.33%	14
2014 Q4	–	Sell	-177,079	Closed	-$12.8M	–	57
2014 Q3	$12.8M	Sell	177,079 -291,021	-62%	-$19.1M	1.48%	31
2014 Q2	$29.1M	Buy	+468,100	New	+$28.3M	3.53%	9

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Redmile Group's BMRN Position: Q2 2026 in Review

Redmile Group increased its BioMarin Pharmaceuticals (BMRN) stake by 53% in Q2 2026, buying an estimated $5M and bringing the position to 265,169 shares worth $15.2M. The position accounts for 1.02% of the portfolio, ranked #22.

Redmile Group first reported a position in BMRN in Q2 2014 and has held it in 13 quarters since. The position peaked at $42.4M in Q2 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Redmile Group held 265,169 shares of BioMarin Pharmaceuticals worth $15.2M as of Q2 2026.
Redmile Group bought 91,310 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $5M.
BioMarin Pharmaceuticals made up 1.02% of Redmile Group's portfolio in Q2 2026, its #22 holding.
Redmile Group first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 13 quarters since.
Redmile Group's BioMarin Pharmaceuticals position peaked at $42.4M in Q2 2023.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.